Together with the above experimental results, these clinical findings provide further, reliable bases for the use of miR-155-targeted therapies to upregulate TLR3 and restrict, via TLR3-induced apoptosis, HCC progression. This evidence concerns the gene TLR3 and hepatocellular carcinoma.